Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma (cohort A) and amyloidosis (cohort B).

Trial Details

NCT ID
NCT04991103
Phase
PHASE2
Sponsor
University of Alabama at Birmingham
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • DaraVRD/DaraVCD
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

  • Age \>18 years with no upper age limit with a diagnosis of newly diagnosed multiple myeloma with indication for initiation of therapy with Eastern …
  • No prior therapy except for dexamethasone (up to 160 mg) and/or bortezomib (up to 5.2 mg/m2 ) and/or cyclophosphamide up to 1000 mg/m2 administered…
  • Measurable disease meeting at least one of the following criteria (at screening or prior to pre induction): 1) Serum monoclonal (M) protein ≥1.0 g/…
  • Life expectancy ≥ 12 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →